Patent 10,357,535 (US) Scope, Claim Coverage, and US Patent Landscape for Lyophilized Daptomycin + Citric Acid
US Drug Patent 10,357,535 is a formulation and use estate built around a specific lyophilized daptomycin matrix with citric acid defined by reconstitution-dependent molarity and tied to reconstitution volume (5 mL to 15 mL) and reconstituted pH (4.0 to 5.0). The claim set creates enforceable coverage for (i) the kit-like product structure (lyophilized drug + citric acid at a target reconstitution molarity), (ii) a reconstituted solution defined by pH and diluent selection, and (iii) methods of treating infections and biofilms using that reconstituted product.
What is US Patent 10,357,535 about and which claim features drive enforceable scope?
Core invention theme: a lyophilized daptomycin formulation where the amount of citric acid in the solid is set so that after reconstitution with 5–15 mL of a pharmaceutically acceptable diluent, the citric acid in solution is 10–500 mM (and narrower dependent ranges such as 25–75 mM). The estate also claims the resulting reconstituted formulation, including a pH window (4.0–5.0) and diluent list, and then uses that reconstituted formulation in treatment and biofilm device exposure methods.
Claim 1 (independent) sets the mechanical boundary for design-around
Claim 1 defines four linked parameters:
- Lyophilized daptomycin formulation containing:
- daptomycin: ~200 mg to ~600 mg
- citric acid: an amount calculated so that after reconstitution:
- citric acid in reconstituted formulation = 10 mM to 500 mM
- Reconstitution volume: 5 mL to 15 mL
- Citric acid specification is reconstitution-defined, not solely as mg per vial.
- The claim is anchored to lyophilized product form.
Enforceable consequence: a competitor must ensure that, under its own label reconstitution instructions and actual formulation composition, the reconstituted citric acid concentration falls outside the claimed molarity band for the defined reconstitution volume range.
Claim 2 narrows the citric acid band to 25–75 mM after reconstitution
Claim 2 depends from claim 1 and locks the reconstituted citric acid concentration to:
- 25 mM to 75 mM (after reconstitution with 5–15 mL).
This is the “high-likelihood” independent-to-dependent enforcement lever because narrower numeric bands are easier to compare to a rival product’s composition and reconstitution instructions.
Claims 3–9 cover the reconstituted solution as a product
- Claim 3: reconstituted formulation comprising the lyophilized formulation of claim 1 plus a pharmaceutically acceptable diluent.
- Claim 4: diluent volume 5–15 mL
- Claims 5–6: pH 4.0 to 5.0
- Claims 7–8: diluent selection from a defined list
- Includes sterile water for injection, bacteriostatic water for injection, saline solutions (0.45%, 0.9%), Ringer’s, lactated Ringer’s
- Claim 8 narrows further to sterile water for injection or 0.9% sterile sodium chloride
- Claim 9: reconstituted citric acid concentration 25–75 mM.
Enforceable consequence: if a competitor’s product is lyophilized with citric acid that lands in the same reconstitution molarity band, it can still fall inside claim coverage even when the opponent’s focus is the reconstituted product’s pH and diluent.
Claims 10–11 add dosage-specific embodiments
- Claim 10: lyophilized formulation with about 500 mg daptomycin, with citric acid configured to yield 25–75 mM citric acid after reconstitution (5–15 mL).
- Claim 11: same but about 350 mg daptomycin.
Enforceable consequence: competitors selling specific vial strengths can be more directly checked against these numeric anchors.
Claims 12–13 expand into methods
- Claim 12: method of treating a bacterial infection by obtaining, reconstituting, and administering an effective amount of the claimed reconstituted formulation.
- Claim 13: method of treating a biofilm by exposing a device surface to a solution of an effective amount of the claimed reconstituted formulation.
Enforceable consequence: once product claims map, these use claims can support infringement theories tied to clinical administration (claim 12) and device-related biofilm protocols (claim 13), depending on how the competitor’s product is used in the real world and how labels/instructions are written.
What do the claim ranges mean practically for formulation and reconstitution infringement?
Key mapping equation: citric acid in reconstituted formulation is set by:
- citric acid mass in the lyophilized vial
- divided by the reconstitution volume (5–15 mL)
- converted into molarity (mM)
Because the claim uses reconstitution-dependent citric acid concentration, a competitor cannot evade simply by choosing a different citric acid mg-per-vial that happens to meet or miss molarity at a single reconstitution volume; it must avoid the claimed molarity band across the claimed reconstitution volume range.
Boundary analysis by claim
| Claim |
Daptomycin amount (lyophilized) |
Reconstitution volume |
Citric acid after reconstitution |
Other required features |
| 1 |
~200–600 mg |
5–15 mL |
10–500 mM |
Lyophilized + citric acid formulation |
| 2 |
(depends on claim 1) |
5–15 mL |
25–75 mM |
Dependent narrowing |
| 3 |
(depends on claim 1) |
not specified |
not specified |
Reconstituted product |
| 4 |
(depends on claim 3) |
5–15 mL |
not specified |
Volume-limited diluent |
| 5–6 |
(depends on claim 3) |
(claim 4/3 context) |
not specified |
pH 4.0–5.0 |
| 7 |
(depends on claim 3) |
(claim 4 context) |
not specified |
Diluent list |
| 8 |
(depends on claim 7) |
(claim 4 context) |
not specified |
Diluent = sterile water or 0.9% saline |
| 9 |
(depends on claim 3) |
(claim 4 context) |
25–75 mM |
Concentration-limited |
| 10 |
~500 mg |
5–15 mL |
25–75 mM |
Citric acid + lyophilized |
| 11 |
~350 mg |
5–15 mL |
25–75 mM |
Citric acid + lyophilized |
| 12 |
n/a |
reconstitute per above |
n/a |
Treat bacterial infection via administration |
| 13 |
n/a |
reconstitute per above |
n/a |
Device surface exposure for biofilm treatment |
How does the pH and diluent limitation affect potential design-arounds?
pH window (4.0–5.0)
Claims 5–6 require:
- reconstituted pH from about 4.0 to about 5.0
A competitor’s product can still meet citric acid concentration bounds while potentially escaping on pH if its formulation yields a reconstituted pH outside the window (or if assay conditions differ, though infringement generally turns on measured product attributes under relevant instructions).
Diluent selection list
Claim 7 includes a broad set of diluents. Claim 8 narrows to:
- sterile water for injection or 0.9% sterile sodium chloride
Design-around lever: if a competitor’s label directs a diluent outside the claim list, it may avoid those specific dependent claims. But it can still be exposed to claim 1–2 and the corresponding reconstitution concentration claims if those dependents do not require that diluent selection.
What is the likely infringement map for a generic daptomycin re-lyophilized product?
A generic or authorized alternative supplier risks infringement if its product:
- Is lyophilized daptomycin with citric acid configured to generate the same reconstitution molarity for the labeled reconstitution volume range; and/or
- Generates a reconstituted citric acid concentration of 25–75 mM and/or reconstituted pH 4.0–5.0; and/or
- Is used under clinical or device protocols that match claims 12–13.
Practical check-list for competitive teams:
- confirm vial strengths (does it match ~350 mg or ~500 mg embodiments)
- obtain label reconstitution instructions (volume range)
- measure reconstituted pH and citric acid concentration under those conditions
- evaluate diluent instructions
This patent’s claim architecture is structured to make those comparisons straightforward.
What patents protect the same lyophilized daptomycin + citric acid concept around US 10,357,535?
The prompt provides only the claims of US 10,357,535, not the bibliographic record (application number, priority date), prosecution history, or the rest of the family. Without those, a complete and accurate enumeration of the full US patent estate covering the same concept (including co-pending continuation families, related salt/stabilizer patents, or composition/pH process patents) cannot be produced.
Accordingly, no additional US patent numbers or family members can be asserted here.
When does US 10,357,535 lose exclusivity, and how does it interact with Orange Book and Hatch-Waxman timing?
The prompt provides no Orange Book listing, drug product reference (e.g., daptomycin brand name), listed patents, FDA approval date, or patent expiration/adjustment numbers. Without those, exclusivity timelines and Paragraph IV or 505(b)(2) timing cannot be mapped to specific FDA milestones.
Accordingly, no exclusivity dates or generic entry windows can be stated here.
What litigation or Paragraph IV challenges could affect freedom to operate for lyophilized daptomycin formulations?
No litigation docket numbers, complaint dates, PTAB records, or Paragraph IV notices are provided. Without court and notice identifiers, a factual landscape of challenges, settlements, or enforceability outcomes cannot be constructed.
Accordingly, no litigation assertions are included.
How does US 10,357,535 compare with alternative daptomycin formulation patent strategies?
Given only the claim text, the comparison can only be made at the conceptual-claim level:
- US 10,357,535 is a stabilizer-and-reconstitution-parameter claim set.
- Many formulation estates in injectables split across:
- alternative stabilizers (e.g., buffer systems, surfactants, chelators)
- pH ranges
- lyophilization-cycle/process parameters
- particle-size or reconstitution-time targets
- device-specific administration and dilution steps
This patent’s distinctive discriminator is the citric acid specification in the reconstituted product tied to reconstitution volume, plus an explicit pH window and a defined diluent list. That combination narrows the scope to competitors whose formulation lands in the same solution characteristics.
Where are the highest-risk claim buckets for competitors?
1) Reconstituted citric acid concentration landing inside 25–75 mM
Claims 2 and 9, and the vial-strength embodiments in claims 10–11, concentrate risk in the 25–75 mM band. If a competitor’s product is used as directed and lands in that band, product-claim exposure is direct.
2) Reconstituted pH inside 4.0–5.0
If the competitor’s formulation achieves the same stabilizer chemistry but yields a reconstituted pH outside 4.0–5.0, dependent claims 5–6 may be avoided, but independent claims 1–2 and dependent claim 4/7/8 structures may remain.
3) Method claims tied to real-world administration and device use
Claim 12 can map to clinical administration if the accused reconstituted product matches the claimed formulation parameters. Claim 13 adds exposure in biofilm/device surface protocols if the claimed reconstituted formulation is used as described.
Key Takeaways
- US 10,357,535 is a lyophilized daptomycin + citric acid patent where the enforceable core is the reconstituted citric acid molarity outcome under 5–15 mL reconstitution volume instructions.
- The claim set adds solution-level constraints: reconstituted pH 4.0–5.0 and diluent selection.
- The estate extends beyond composition into method-of-treatment and biofilm/device surface exposure using the claimed reconstituted formulation.
- For freedom-to-operate, the operational infringement tests are measurable: citric acid concentration after reconstitution, reconstitution volume range, pH, and diluent instructions, plus how the product is administered/used.
FAQs
1) What must a competitor match or avoid under claim 1 of US 10,357,535?
Avoid having the citric acid concentration in the reconstituted product fall within 10–500 mM when reconstituting with 5–15 mL, where the product is a lyophilized daptomycin containing about 200–600 mg daptomycin.
2) Which dependent claims are the tightest numeric constraints?
Claims 2 and 9 (citric acid 25–75 mM after reconstitution) and claims 10–11 (embodiments at about 500 mg and 350 mg daptomycin with citric acid set to yield 25–75 mM).
3) Can a competitor evade by changing the diluent?
Changing diluent may avoid dependent claims 7–8, but it does not necessarily evade claims 1–2 if reconstituted citric acid molarity and lyophilized composition still fall within the claimed bounds.
4) Does pH matter if citric acid molarity is within range?
Yes for dependent claims 5–6 because they require a reconstituted pH of 4.0–5.0. Independent coverage may still exist depending on the accused product’s citric acid concentration window.
5) What does claim 13 cover from a practical standpoint?
Exposing a device surface to a solution of an effective amount of the reconstituted daptomycin formulation for biofilm treatment, using the claimed formulation parameters.
References
No sources were cited because the prompt does not include bibliographic or FDA/Orange Book or litigation records for US 10,357,535.
